ADDED
All statements other than statements of historical facts contained in this Annual Report are forward-looking statements.
Recent and future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial condition.
If we are unable to acquire and retain customers for our Molecule.ai platform or if any of such customers renew licenses at lower prices, our future revenues may be negatively impacted.
While our Company s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
Our ability to satisfy the continued listing requirements of the Nasdaq Capital Market and maintain the listing of our common stock.
Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.
Our board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to holders of our common stock and such issuance could potentially adversely affect stockholders voting power and perpetuate their control over us.
Business On November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company building an artificial intelligence ( AI ) driven platform for molecular discovery and early-stage drug development.
By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform (hereafter, Molecule.ai or the platform ) helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.
The platform is engineered to accelerate the iteration cycles that characterize modern drug discovery while preserving scientific reproducibility, traceability and operational reliability.
REMOVED
All statements other than statements of historical facts contained in this Form 10-K are forward-looking statements.
Business We are a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy.
Radiation therapy ( RT ) is one of the most effective modalities for treating cancers.
We are developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT.
We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
The corporate structure is based on Shuttle Pharmaceuticals Holdings, Inc.
(Nasdaq SHPH a Delaware company) serving as a holding company with drug discovery and development performed in the Company s wholly-owned subsidiary Shuttle Pharmaceuticals, Inc.
(a Maryland Company) and diagnostics performed in the Company s wholly-owned subsidiary Shuttle Diagnostics, Inc.
Our product candidates include Ropidoxuridine, a Phase II clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets the PC-RAD Test, a blood test to predict clinical response to radiation therapy and the PSMA-B ligand for potential use as a theranostic agent.